












Abstract: Today, in most European countries, 
residential treatment programmes form an 
important element of the range of treatment and 
rehabilitation options for drug users. The aim of 
this paper is to provide a Europe-wide overview 
of the history and availability of residential drug 
treatment within wider national drug treatment 
systems. To help with this, the paper describes 
the history and availability of residential 
treatment in Europe and develops a 
categorisation of the broad range of available 
models and treatment approaches applied in 
residential settings. Countries differ in the level of 
residential treatment provision. Over two-thirds of 
the 2 500 reported facilities in Europe are 
concentrated in just six countries, each reporting 
over 100 facilities. A description is provided of 
the characteristics of residential treatment 
(inpatient) clients, as well as discussion of 
organisational and quality assurance issues 
relevant to residential treatment and how these 
matters are dealt with across Europe.
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treatment demand indicator (TDI). In the 22 European 
countries providing data, around 35 000 drug clients entered 
inpatient treatment in 2011, with those entering inpatient 
centres representing only around 11 % of all reported drug 
clients in Europe. This suggests that, on average, around one 
person commences inpatient treatment for every 10 people 
starting specialist outpatient treatment. However, substantial 
inter-country differences exist. Typically, inpatient clients are 
male and in their early 30s. Compared with outpatient 
treatment entrants, they live in more disadvantaged social 
conditions (low education, unstable living conditions and 
unemployment). Just under half of inpatient clients enter 
treatment for problems related to primary use of opioids 
(mainly heroin). 
In most European countries, funding for residential treatment 
is provided by governments, typically in the context of a joint 
funding arrangement either between different levels of the 
government or in tandem with health insurance. In a number 
of countries, drug users make some personal contribution to 
residential treatment. To aid quality assurance and improved 
processes in residential treatment, a considerable number of 
Member States note the existence and use of evidence-based 
clinical guidelines and service standards.
I 1. Introduction
I Background and aims
Latest estimates suggest that, while almost three-quarters of a 
million problem opioid users are receiving opioid substitution 
treatment in Europe, at least a quarter of a million drug users 
are receiving other forms of treatment, including a range of 
approaches in residential settings. Most people receiving 
specialist treatment for drug problems may not need to access 
residential treatment. Their needs can be met appropriately by 
community drug treatment services, which have increased in 
availability and effectiveness over the past decade. However, 
outpatient treatment and rehabilitation may not always be the 
most appropriate option, particularly for a select group of 
drug-dependent clients who need the safety and structure that 
residential treatment can provide. Hence, residential drug 
treatment is a sizeable and necessary element in the range of 
treatment options available to drug users.
While measuring and improving drug treatment provision and 
outcome in opioid substitution treatment have been high on 
the research agenda in recent years, the extent and nature of 
residential treatment has received less research attention. 
Addressing this information gap is likely to benefit funding 
I Summary
‘Residential treatment’ comprises the provision of a range of 
treatment delivery models or programmes of therapeutic (and 
other) activities for drug users, within the context of residential 
accommodation, in either the community or a hospital setting. 
The main therapeutic approaches used include the 12-step/
Minnesota model, therapeutic community and cognitive–
behavioural (or other) therapy-based interventions.
In Europe, trends in the development of residential drug 
treatment closely mirror broader social trends in institutional 
care. This has included an initial ‘psychiatric’ phase followed 
by a more liberal ‘social therapy’ phase in the second half of 
the 1970s, involving the family and social environment of drug 
users; the grass-roots initiatives by self-help groups were 
followed by a period of professionalisation of therapeutic staff 
and quality management. The 1970s and 1980s saw an 
expansion in residential care, followed by a contraction in 
favour of community-based outpatient treatment; and the 
objectives of drug treatment changed from a sole focus on 
abstinence to integrating the reduction of harm. In the history 
of residential drug treatment, each country retains its own 
‘story’ of the emergence of drug use problems. A large part of 
the earlier sociopolitical debates reflected national culture and 
values and determined changes in national health systems 
and funding streams. However, the HIV/AIDS crisis of the 
1980s had a profound impact on the residential treatment 
response to drug addiction across many European countries, 
leading to the scaling up of more varied treatment offers 
within an integrated system of responses to drugs.
Today, in most European countries, residential treatment 
programmes form an important element of the range of 
treatment and rehabilitation options for drug users. Countries 
differ, however, in the level of residential treatment provision. 
Over two-thirds of the 2 500 reported facilities in Europe are 
concentrated in just six countries, each reporting over 100 
facilities, with Italy reporting the highest number (708 
residential facilities). There is also variation in the treatment 
approaches used to treat drug-using clients in residential 
settings in Europe today. Although in 15 countries the 
approach/principles of the therapeutic community were 
identified as predominant — employed by all or most of the 
residential programmes in their territory — a combined clinical 
practice, rather than fidelity to one treatment approach, is 
widely accepted. Although, historically, residential treatment 
programmes have been exclusively drug free, current data 
indicate the growing importance of providing medication to 
substitute for illicit opioid use.
The best available information source to describe the profile of 
drug clients entering residential treatment in Europe is the 
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bodies, which need to understand the nature of residential 
programmes and the extent of services offered in order to 
make treatment more effective and cost-effective with respect 
to the range and amount of services offered. Clients and their 
families too can use such information to gain insights about 
the nature of treatment and the approaches that may be used 
— erroneous client expectations about treatment can lead to 
higher rates of dropout, client perceptions of failure and 
inefficient use of treatment resources. Although such 
arguments apply to all forms of treatment, they are particularly 
relevant to residential treatment because of the high cost of 
this treatment provision.
There is a wide range of different types of residential treatment, 
and residential treatment is advancing and currently 
developing its evidence base. To aid comparison, it is 
important to establish common factors and models among this 
variety. Traditionally, residential programmes have been 
delivered over a number of months, up to a year, to allow 
successful achievement of treatment goals. In the current 
unfavourable economic conditions, it is particularly relevant to 
examine whether and how the pattern of residential treatment 
provision is changing and how providers are responding to new 
demands and opportunities — in terms not only of treatment 
duration, but also of programme content and intensity.
The aim of this publication is to provide a Europe-wide 
overview of the history and availability of residential drug 
treatment within wider national drug treatment systems. To 
facilitate this, this paper develops a categorisation of the 
broad range of available models applied in residential settings. 
Finally, it describes the characteristics of residential treatment 
clients, as well as presenting and discussing key features of 
the organisational issues around this type of treatment. This 
publication is descriptive in nature and does not attempt to 
consider the effectiveness of residential programmes for drug 
users. An assessment of the evidence base, with a focus on 
therapeutic communities, and an evaluation of therapeutic 
communities’ impacts are reviewed and reported elsewhere 
(EMCDDA, 2014).
Like other parts of the health and social sector, drug treatment 
systems are under increasing pressure to demonstrate value 
for money. In this context, this publication builds on the 
collaboration with the Reitox national focal points to inform 
discussions about the contribution that residential treatment 
makes to the drug treatment systems across Europe, as well 
as acting as a baseline for assessing future changes in the 
pattern of residential services’ design, function and provision.
I Scope and coverage
Residential treatment may be defined in a number of different 
ways. For example, it might be defined as one or more of a 
broad range of therapeutic interventions provided within the 
context of residential accommodation, or a definition might 
require a minimum duration of treatment. For the purposes of 
this publication, residential treatment programmes are 
defined as involving therapeutic interventions aimed at 
long-term change in drug use, usually alongside the other 
rehabilitative activities, within a residential setting.
It is important to note that residence can occur within a range 
of settings: community-residential, hospital and prison 
environments. This publication focuses on treatment facilities 
in community-residential and hospital settings; drug 
treatment provision in prison is considered in the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
Selected issue Prisons and drugs in Europe: the problem and 
responses (EMCDDA, 2012a). This publication does not 
include data and information about supportive residential 
programmes dedicated to the provision solely of social 
support (e.g. shelters, supported housing services), although 
these may have a role in the treatment, care and support of 
drug users in different stages of their recovery. In some 
instances, the boundaries may be blurred between some 
types of supported housing services and residential 
treatment, as supported accommodation services may have 
similar treatment aims and may provide a structured daily 
programme of activities for their residents.
The goals of residential treatment programmes generally are 
to prevent a return to active drug use, provide individuals with 
healthy alternatives to drug use and help drug users to 
understand and address the underlying factors supporting 
drug use and make healthier decisions (NTA, 2006). 
Residential programmes thus potentially offer a number of 
benefits in a coherent package that removes people from their 
drug-using environment and provides a safe and supportive 
place to learn the skills conducive to living a sober and 
rewarding life. However, changing views on addiction as a 
chronic disorder and emerging theoretical insights that 
question treatment episodes in closed environments are likely 
to have an impact and prompt changes in the treatment goals 
and methods of residential programmes (McLellan et al., 
2000).
In this report we distinguish between inpatient detoxification 
and residential treatment. The main differences are in terms of 
aims and interventions. Inpatient detoxification provides safe 
withdrawal from a drug of dependence — not so much a form 
of treatment but a gateway to treatments that are aimed at 
long-term change. Residential treatments aim to help 
individuals to attain control over drug use, achieve recovery 
from drug problems, improve health and well-being and 
change lifestyle, including family and social relationships, 
education, voluntary activities and employment. Key features 
of such programmes include the provision of individually 
tailored psychosocial support and a structured programme of 
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I  Residential addiction care in Europe at the end of the 1960s
Until the late 1960s, no specific drug-related treatment 
system existed. Addiction was mainly taken care of by the 
general health system and in most countries consisted of 
medico-psychiatric care delivered in inpatient wards of 
psychiatric hospitals; alcohol users constituted the main client 
group. Early initiatives in outpatient treatment for people with 
alcohol problems were reported from the Netherlands (1910), 
and in the UK (1) from the 1920s medical doctors were able to 
prescribe maintenance with opioids to addicted patients in an 
outpatient regime. Dedicated addiction facilities such as the 
‘therapeutic farm’, established in 1932 in Alsace as France’s 
first residential facility for the treatment of alcohol 
dependence, were a rarity.
An alternative, democratic and user-led form of therapeutic 
environment, therapeutic communities, were introduced in 
psychiatric hospitals in the UK in the 1940s (Jones, 1953). 
They represented a shift from individually oriented psychiatric 
treatments to a group therapy approach with a focus on social 
interaction, based on a psychological and social perspective 
of mental illness which had gained ground in psychiatry. These 
developments also affected the treatment of addiction in 
psychiatric wards. At the same time, other new approaches, 
specific to the treatment of addiction, developed, such as the 
‘Apolinar’ residential unit in Prague, which combined medical 
treatment with collective education and behavioural 
approaches in the treatment of patients dependent on alcohol, 
medical opioids, stimulants or inhalants. Another innovative 
initiative was the ‘alternative therapeutic community’ set up by 
Janez Rugelj in Slovenia and based on a treatment method he 
invented, which entailed an ‘open’ (outpatient) therapeutic 
group setting for up to 120 members with different addictions, 
including gambling and eating disorders, who could join and 
leave the programme freely. These pioneering units later 
became models for other specialised residential addiction 
treatment in their own countries and abroad. In the European 
countries forming part of the Soviet Union, drug use was not a 
topic of public discussion during this period.
I  The creation and expansion of specialised residential treatment facilities for drug addicts (late 1960s until early 1980s)
In the late 1960s and during the 1970s, the spreading use of 
illicit drugs was reported from a number of countries, 
including Belgium, Denmark, Germany, France, Italy, the 
Netherlands, Sweden, Norway and the UK. In 1972 in the 
Netherlands, fuelled by economic recession and 
unemployment, heroin use reached epidemic proportions for 
(1)  In 1965, prescribing of narcotic drugs was temporarily possible in Sweden.
daily activities that residents are required to attend over a 
planned period of time. There may also be an initial 
detoxification phase in the programme.
I 2.  Historical perspective of residential treatment for drug users
This section provides an overview of how the activities and 
organisation of residential drug treatment in Europe have 
changed during the last half century. That forms a backdrop 
against which current practice may be considered.
Data on residential treatment in Europe for this report are 
primarily sourced from the Reitox national focal points 
— the EMCDDA’s network of national partners in the 
28 EU Member States, as well as Turkey and Norway — 
supplemented by treatment demand data routinely 
collected by the EMCDDA and reports in the scientific 
literature.
The sources used to provide the information included 
were varied and ranged from national statistics through 
online directories of facilities to expert impression and 
estimation. The report needs to be read with that caveat 
in mind.
The ‘Residential treatment clients’ section draws on the 
EMCDDA’s treatment demand indicator (TDI) database, 
which covers around 60 % of existing residential units in 
the reporting countries and does not include data and 
information on residential units in six countries (Spain, 
Italy, Portugal, Slovenia, Latvia and Lithuania).
‘Residential treatment’ is defined as a range of treatment 
delivery models or programmes of therapeutic and other 
activities for drug users, including the 12-step/Minnesota 
model, therapeutic community and cognitive–
behavioural (or other) therapy-based interventions, within 
the context of residential accommodation in the 
community or hospital setting. This definition excludes 
(i) programmes providing inpatient detoxification only, 
(ii) drug treatment provision in prison (reviewed by the 
EMCDDA, 2012a) and (iii) supportive programmes 
dedicated to the provision solely of social support 
(e.g. shelters, supported housing services).
Data sources and definitions used for this 
report
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Thus, this period saw the establishment of specialised drug 
treatment facilities and then the rapid expansion of residential 
drug treatment in the European countries hit by the heroin 
epidemic. Drug-free TCs initiated by ex-users and their 
families predated the establishment of public services in 
many countries and became the ‘reference’ for residential 
treatment until AIDS called into question professional 
practices based solely on abstinence.
I  Adaptation of the treatment landscape in Europe in response to the HIV/AIDS epidemic and the current situation (mid-1980s until today)
AIDS was first diagnosed in 1981 in the USA and shortly 
afterwards in Europe. When HIV testing became available in 
1985, large numbers of injecting heroin users were found to 
be infected. As the HIV epidemic swept over much of the 
European region, it highlighted the need for greater treatment 
capacity and for a different approach that was able to reach 
problem heroin users who were not in contact with treatment 
services. The result was a drastic reshaping and expansion of 
the drug treatment offer, including outreach work, low-
threshold facilities and opioid substitution treatment, 
delivered to heroin users in the framework of community-
based outpatient services.
In the second half of the 1980s, church-led residential 
programmes were established in several countries where drug 
treatment did not exist before, such as Hungary in 1986 and 
Malta in 1989; and, in the 1990s, TCs with a religious 
orientation were founded in Croatia. Several European 
countries experienced an increase in the use of illicit drugs 
only in the course of the 1990s, following the opening of 
borders after political change (Hungary, the Czech Republic, 
Slovakia, Bulgaria and Romania) or regaining independence 
(Estonia, Latvia and Lithuania). In these cases, the 
establishment of new residential treatment in the 2000s may 
have benefited to some extent from international training 
initiatives (e.g. US-led training of 50 Bulgarian professionals), 
from exchange with European professionals through networks 
and at conferences and from information about best practice 
in drug treatment interventions made available online since 
the late 1990s (EMCDDA website: Exchange on Drug Demand 
Reduction Action (EDDRA)).
Today’s drug treatment systems in Europe are characterised 
by a broad and diversified range of providers and 
interventions. The provision of outpatient treatment, in 
particular, has increased considerably since the beginning of 
the 2000s, encompassing a range of services. Residential 
treatment facilities in most countries form a small but 
essential part of the overall treatment response to drug use in 
national drug systems. The best indication currently available 
of the share of treatment provided through residential 
the first time. By the early 1980s, however, heroin use had 
markedly increased in several countries, including Germany, 
Greece, France, Italy, Luxembourg, Spain, Sweden, Norway, 
Portugal and the UK, and, in Poland and Lithuania, the 
injecting of opioids extracted from poppy plants had become 
popular.
Adolescent drug users represented a new type of client in the 
1970s and were a challenge for existing addiction services, 
where psychiatric approaches dominated and which had thus 
far mainly focused on treating alcohol dependence. In 
response to this increasing prevalence of drug use, new 
specialised treatment centres began to emerge and new 
policies and laws were adopted in European countries, which 
paved the way to channel public funding into specialised drug 
treatment facilities. For example, in Germany, addiction was 
recognised as a disease in 1968 and costs for treatment were, 
henceforth, to be covered by public insurance funds; in Austria 
in 1971, the need for health and social interventions was, for 
the first time, clearly defined in an amendment to the narcotics 
act; and, in France, the law of 31 December 1970 opened the 
door to state funding for various new and sometimes 
experimental treatment initiatives, including therapeutic 
apartments, foster families and facilities in rural environments, 
offering ‘a way back to healthy living’ to drug users.
During the 1970s and 1980s, self-help groups such as 
Release (UK) and ex-addicts took the lead in developing 
treatment programmes and centres in several countries. For 
example, in 1978, Marek Kotanski established the first Monar 
therapeutic community (TC) in Poland. It became the nucleus 
of the Monar youth association, which set up another 10 
Monar TCs under a funding agreement with the Ministry of 
Health. Religious-led treatment centres also emerged — 
mainly in the Catholic countries of the south — as well as the 
model of hierarchically structured drug-free clinics, following 
the Alcoholics Anonymous (AA)-inspired TC model of Synanon 
and other US models (e.g. the first Phoenix house in Europe 
was opened in London in 1970).
In the course of the 1970s in the UK, the widespread general 
practitioner-led maintenance prescribing model was replaced 
by much more controlled prescribing by psychiatrists in 
specialised regional drug-dependence clinics, based at 
hospitals. In the early 1980s, residential care was available in 
14 drug-free rehabilitation houses, typically located far away 
from inner-city areas where drug use often concentrated.
In the countries of the Soviet Union, the public image of 
addicts as offenders dominated and compulsory treatment of 
drug users was introduced in the 1970s. People diagnosed as 
dependent had to undergo 60 to 90 days of hospital treatment 
and were sent to work regime treatment if they did not comply 
(Latypov, 2011).
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Twelve countries reported the existence of residential facilities 
in both the community and hospital environments. In four 
countries, hospital-based residential facilities make up the 
bigger share of available residential treatment facilities — just 
over half in Belgium and Ireland and three-quarters in Bulgaria 
and Latvia.
TABLE 1
Number of residential facilities in community and hospital 







Belgium 14 17 31
Bulgaria 5 15 20
Czech Republic 18 15 33
Denmark 31 0 31
Germany 320 0 320
Estonia 8 0 8
Ireland 41 67 108
Greece 11 1 12
Spain 207 1 208
France 44 0 44
Croatia 30 0 30
Italy 708 0 708
Cyprus 2 1 3
Latvia 1 3 4
Lithuania 25 0 25
Luxembourg 1 1 2
Hungary 14 0 14
Malta 7 0 7
Netherlands 80 0 80
Austria 24 0 24
Poland 79 0 79
Portugal 68 0 68
Romania 9 3 12
Slovenia 7 0 7
Slovakia 33 0 33
Finland 75 n/a 75
Sweden 311 0 311
UK 120 18 138
Turkey  n/a  n/a  n/a
Norway 37 28 65
Total 2 330 170 2 500
Notes:
Czech Republic: reported ranges are, for community residential facilities, n = 15–20 
and, for hospital-based facilities, n = 13–17, of which the means (n = 18 and n = 15 
respectively) are used to calculate the total number of residential facilities.
Netherlands: 80 residential treatment facilities are treatment units (i.e. parts of 
big addiction treatment centres). Each of these centres has a number of different 
units spread over the region in which they are operating.
Ireland: 2010 data. The figures present numbers of facilities reporting to the 
National Drug Treatment Reporting System; not all units in the country report to 
the system. In addition, these figures include inpatient services, which provide 
detoxification only and/or treat only problem alcohol use.
France: 2013 data.
Finland: 2010 data; estimate based on the Register of Institutions in Social 
Welfare and Health Care; hospital data could not be accessed, as hospitals are 
analysed as single entities and are not analysed by specialisation.
Luxembourg: hospital-based facility operational only since 2012.
n/a: not available.
treatment at the European level is the share of treatment 
demands collected through the EMCDDA treatment demand 
indicator (TDI) and this will be explored in the context of an 
overview of residential treatment clients (Section 4).
I 3.  Extent and nature of residential treatment
This section addresses issues related to the availability of 
treatment in residential settings in Europe and its place in 
drug treatment systems today. This is followed by a 
description of residential treatments along two dimensions: 
(i) therapeutic approach and (ii) treatment components. 
Finally, this section outlines the provision of residential 
treatment for specific client groups, highlighting examples of 
implementation and good practice and what is known about 
what works.
The aim is to give an indication of the availability and degree of 
variability across Europe, in terms of the:
n  number of facilities (national availability);
n  therapeutic models employed;
n  typical planned treatment duration.
I Availability of treatment facilities in Europe
This review identified 2 500 residential treatment facilities 
providing services for drug users (Table 1). Italy, Germany, 
Sweden, Spain, the UK and Ireland reported over 100 facilities 
each and between them accounted for over two-thirds of all 
reported facilities in Europe. These facilities are divided into 
two broad groups based on the setting — community-
residential or hospital — for service delivery:
1.  Community-residential facilities — residential facilities 
within the community for the treatment of clients with 
drug-use problems.
2.  Hospital-based facilities — providing beds for the 
treatment of clients with drug-use problems in a hospital 
environment. These can be either stand-alone facilities 
used for nothing but treatment of clients with drug-use 
problems or wards within psychiatric or general medical 
facilities that are theoretically available for drug users but 
in practice could be and are occupied by general or medical 
psychiatric clients.
Community-residential facilities form the larger group 
(n = 2 330), with 17 countries reporting all of their residential 
facilities to be of this variety, and 170 hospital-based ones 
exist across Europe.
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interventions. Based on key characteristics of individual 
residential programmes, the following main distinct types of 
residential treatment can be identified: 12-step/Minnesota 
model, therapeutic community approach and psychotherapy-
based, using either CBT or other models.
However, treatment programmes often involve combinations 
of goals and activity components that are determined by 
programme directors and staff beliefs about effective drug 
treatment, staff training and experience, and the types of 
clients in the programme. Staff may adhere to one or two 
primary approaches, or they may be eclectic and combine 
multiple orientations and approaches.
Therapeutic approaches may be delivered one to one and/or 
in group format. Typically, these interventions are specific to 
the tasks and challenges faced at each stage of the treatment 
process and enable staff members to use suitable stepwise 
approaches in developing and using treatment protocols.
Therapeutic community approach
The therapeutic community (TC) approach has many features 
in common with 12-step treatments. Both approaches focus 
on abstinence as the overriding goal of treatment and see 
recovery from addiction as requiring a restructuring of 
thinking, personality and lifestyle in addition to giving up 
drug-taking behaviour. The key distinction of the TC approach 
is the use of the community itself as a fundamental change 
agent (‘community as a method’) (De Leon, 2000).
Two of the defining features of the ‘community as method’ are 
a community environment with a range of structured activities 
where both staff members and residents are expected to 
attend community meetings and share activities; and the 
notion of peers as role models who give the right example by 
living according to the TC’s philosophy and value system. At 
first, residents are completely isolated from their former life 
and are not permitted to have visitors, letters or telephone 
calls. Daily life within the community is very structured and 
with little opportunity for doing anything alone. This forces 
interaction with other residents and permits constant scrutiny 
of their behaviour by their peers. Residents who show 
personal growth in terms of honesty and self-awareness move 
up in the hierarchy, assuming greater responsibilities and 
increased privileges, so that senior residents become models 
for new residents.
A recent systematic review (EMCDDA, 2014) of the evidence 
for the TC approach — the most widely applied approach in 
residential settings in Europe — found that studies conducted 
in North America suggest that therapeutic communities are at 
least as effective for the treatment of addiction as other 
(residential or community) interventions in terms of lowering 
However, care is needed in interpreting these data. For 
example, the facilities can vary considerably in size, as do the 
populations that they serve and the prevalence of drug 
problems in the different countries. The completeness of the 
information may also vary; for example, in Ireland, the 
information covers only those facilities that report to the 
National Drug Treatment Reporting System and, in Finland, 
hospital information was not available.
I  Therapeutic approaches used in residential facilities in Europe
Residential treatment programmes aim to foster recovery 
beyond detoxification and stabilisation, focusing on health, 
personal and social functioning and enhanced quality of life. 
These programmes, however, can differ markedly, as they can 
be based on a number of different therapeutic approaches 
(or philosophies) and employ a range of different treatment 
components (or interventions).
Therapeutic approaches relate to the programme’s theoretical 
underpinnings, ethos and method of delivering programme 
The main therapeutic approaches found in residential 
treatment programmes in Europe are based on:
n  therapeutic community principles — in a programme 
using therapeutic community principles, the pillars of 
the therapeutic process are self-help and mutual 
self-help; clients and staff live together in an 
organised and structured way that promotes change 
and makes possible a drug-free life in society;
n  12-step/Minnesota model — in a programme with a 
12-step orientation, group sessions focus primarily on 
encouraging clients to accept that drug dependence 
is a disease;
n  psychotherapy, using:
–  cognitive–behavioural therapy (CBT) — in a 
programme with a CBT orientation, group sessions 
emphasise helping residents to identify situations 
in which there is a risk of relapse and to learn 
appropriate coping responses; or
–  other psychotherapeutic models, for example 
psychodynamic, gestalt, family-oriented.
However, some residential treatment programmes use a 
mixture of approaches.
What are the main therapeutic approaches 
that guide residential services provision?
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carried out so that the current behaviours and ways of thinking 
are understood, goals are identified and the ways of achieving 
these goals are defined. According to the individual analysis, 
the resident’s programme may be narrow, focusing only on the 
problem of drug use, or broad, encompassing a range of 
related problems and dealing with various aspects of the 
individual’s behaviour and belief system.
There is a ‘family’ or collection of cognitive–behavioural 
approaches rather than a single cognitive–behavioural 
method. This includes motivational interviewing (MI) (Miller 
and Rollnick, 1991, 2002), aimed at enhancing an individual’s 
motivation to change by exploring and resolving ambivalence 
and helping the resident to clarify goals and commit to 
continuing change; relapse prevention (Marlatt and Gordon, 
1985), aimed at developing the resident’s ability to recognise 
cues and to intervene in the relapse process so that lapses 
occur less frequently and with less severity; and behaviour 
modification (Skinner, 1953; Bandura, 1969), focused on 
arranging contingencies of positive reinforcement to develop 
and maintain appropriate patterns of behaviour.
One systematic review of the evidence on the effectiveness of 
residential programmes indicated that treatment programmes 
based on a CBT model (or a mixed 12-step/CBT model) can 
be effective in reducing drug use and associated problems 
among people with dual diagnoses (Brunette et al., 2004).
Combined approaches
Combined approaches, sometimes called integrative or 
eclectic approaches, combine two or more therapies to 
maximise a person’s progress. Sometimes, staff at residential 
programmes would have a primary orientation, such as CBT, 
but supplement it with techniques from family therapy, giving 
an eclectic identity to the residential programme. Combined 
approaches have a broader theoretical base and may be more 
sophisticated than approaches using a single theory. They 
offer greater flexibility in treatment — individual needs are 
potentially better matched to treatment when more options 
are available. However, the lack of a defined therapeutic 
approach may result in the loss of theoretical background and 
identity, thereby rendering the programme less amenable to 
evaluation and its nature less understandable to clients, their 
families and funding bodies.
Distribution of different therapeutic approaches in 
Europe
Although all the above types of therapeutic approach can be 
found within European residential treatment facilities, 
identifying the specific categorisation that applies to each 
facility is difficult. For instance, in the majority of countries, 
drug and alcohol use and recidivism rates. These findings, 
however, are predominantly based on imprisoned drug users; 
similar evidence for the effectiveness of community 
residential treatment using the TC approach has yet to be 
developed. The same review found that European studies on 
therapeutic communities show improvements on a number of 
outcomes (e.g. drug use, recidivism, quality of life, health) 
measured at different time points after treatment. However, 
because of the observational nature of the studies conducted 
in Europe and the related methodological limitations, the 
possible conclusions that can be drawn remain tentative.
12-step/Minnesota model
Both 12-step and Minnesota model programmes owe their 
origins to the influence of Alcoholics Anonymous (AA), which 
views addiction as a disease. The two types of treatment have 
a number of features in common, although Minnesota-type 
treatment is typically delivered by professionals and is less 
reliant on self-help components than 12-step treatment. Both 
types of programmes generally provide a highly structured 
and relatively short (three to six weeks) package of residential 
treatment involving an intensive programme of daily lectures 
and group meetings designed to implement a treatment plan 
based upon the 12 steps. This usually involves an initial 
therapeutic rehabilitation phase, in which residents work with 
therapists individually and in groups to analyse their 
personality and their patterns of behaviour. Much of the focus 
of this initial phase is around dealing with the issues that led 
the individual into active addiction. This is followed by 
therapeutic work centred on ‘starting on the path to a new life’, 
which, while maintaining a clear therapeutic philosophy and 
approach, is very much about developing the key skills needed 
for a new life.
Two systematic reviews of the evidence on the effectiveness 
of residential programmes indicated the effectiveness of 
treatment programmes based on a 12-step/Minnesota model 
(or a mixed 12-step/CBT model) in reducing drug use and 
associated problems among adolescents (Elliott et al., 2005) 
and people with dual diagnoses (Brunette et al., 2004).
Cognitive–behavioural therapy
Cognitive–behavioural therapy is a general therapeutic 
approach that seeks to modify negative or self-defeating 
thoughts and behaviours. CBT uses the resident’s thinking 
errors (cognitive distortions) as the basis for identifying 
activities to promote behavioural change. The principle is to 
find out which modifiable behaviours and beliefs are 
maintaining drug use and to decide what change is wanted 
and how this change can be achieved. Thus, before therapy 
can be initiated, a behavioural and/or cognitive analysis is 
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many of the residential facilities state that they use a number 
of different programmes and neither offer any indication of 
their primary or predominant approach nor indicate if the 
programme that would be used depends on the individual 
presenting for treatment.
Furthermore, there is substantial variation among countries in 
the capacity to classify residential treatment facilities and, at 
the national level, a range of approaches may be adopted to 
gather information that helps to associate facilities with a 
predominant therapeutic approach. In Denmark, indicators 
such as the number of employees trained in a certain 
treatment approach or school of psychotherapy were used to 
guide the classification of residential facilities; in Hungary, 
national associations and relevant therapy institutes were 
approached to access relevant information and to determine 
the correct assignment of residential facilities to one of the 
above categories.
For each country, the total numbers of residential facilities 
that do and do not provide information on their predominant 
treatment approach were established. The latter were grouped 
and marked as having a ‘combination of approaches’.
Overall, of the 2 500 reported residential facilities, 46 % 
(1 160) followed therapeutic community principles. The 
philosophy of the remaining facilities could be described as 
‘combined’ (38 %; n = 942), CBT-based (7 %; n = 163), based 
on some other psychotherapy approach (5 %; n = 131) or 
12-step/Minnesota type (4 %; n = 104) (Figure 1).
There was some variation between countries in the 
therapeutic approaches used by residential facilities 
(Appendix 1).
The TC approach or its principles represent the predominant 
treatment approach applied in all or most residential facilities 
in 15 countries. CBT is applied in most residential facilities in 
Belgium, Bulgaria, Austria and Norway. Most facilities in 
France and Cyprus identify themselves with other 
psychotherapy approaches such as psychoanalysis and family 
therapy, whereas 12-step-oriented facilities prevail in Estonia. 
Although residential facilities in most countries can be 
associated with a predominant therapeutic approach, a 
combination of approaches is used in most residential 
facilities in Germany, Ireland, the Netherlands, Slovakia, 
Finland, Sweden and the UK. Figure 2 shows the reported 
predominant therapeutic approach in residential facilities in 
Member States as a percentage of the total number of all 
residential facilities in the country.
I  Planned treatment duration in residential programmes
Treatment duration has been shown to be related to improved 
outcomes in a number of studies (see Box ‘Duration of 
treatment’) and a minimum threshold of three months for 
treatment impact has been identified. The residential 
programmes identified in this study can be categorised 
according to their reported planned treatment durations, as 
short-term (planned stay of three months or less) and longer-
term (planned stay of more than three months). The planned 
treatment duration for the majority of programmes is over the 
threshold of three months, but some are shorter. The duration 
varies according to the therapeutic approach adopted. 
FIGURE 1












Therapeutic community  
principles 46 %
FIGURE 2
Predominant therapeutic approaches in residential facilities 
as a percentage of the total number of residential facilities
 Therapeutic community /Therapeutic community principles   
 Psychotherapy/cognitive behavioural therapy   Psychotherapy/other  
 12-step/Minnesota   Combined   No data
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an era of spending cuts, planned residential treatments 
typically last less than 24 weeks, and are most often offered 
for 12 weeks.
However, individuals may drop out of treatment before it is 
completed, and this may be a more common reason for 
treatment duration being below the minimum threshold. The 
length of stay is shaped by both programme characteristics, 
such as therapist caseload size and the balance between 
therapy, demand for domestic duties and ‘programme-free’ 
time (Meier and Best, 2006), and individual client features, 
such as motivation for change and treatment readiness (Meier 
et al., 2005).
Promising practices in enhancing engagement and retention 
include:
n  the use of motivational interviewing (e.g. Carroll et al., 
2006);
n  using more senior staff to induct new residents into 
treatment (e.g. De Leon et al., 2000);
n  increasing the focus on the therapeutic relationship in staff 
training and supervision (e.g. Meier et al., 2006).
Although the application of the above means a more resource-
intensive approach, it is linked with earlier client engagement 
in the treatment process, which, in turn, is linked to better 
retention and improved outcomes (Simpson, 2004).
I 4.  Treatment elements in residential programmes
Having provided an overview of the therapeutic approaches 
used within residential programmes in Europe, this section will 
consider the different elements or phases of the treatment 
process. Treatment elements are the specific change 
techniques or services that can be offered at different points 
within each treatment approach to achieve certain goals and 
meet individual clients’ needs. The categorisation of these 
components is not standardised and the terminology differs 
across countries and facilities in Europe. Nonetheless, the 
principal elements include stages such as intake assessment, 
treatment planning, treatment implementation and continuing 
care, sometimes called aftercare (Figure 3), as well as specific 
therapeutic (psychotherapy and pharmacotherapy) and social 
reintegration (e.g. education, vocational skills training, 
volunteering opportunities) interventions, which may be used 
at different times over the course of the residential treatment 
programme.
While outlining all treatment elements, this paper focuses 
greater attention on two of them: pharmacotherapy in 
Three-quarters of residential programmes following the 
12-step approach or applying some form of psychotherapy 
have a planned treatment duration of three months or more. 
Additionally, the majority of TCs and programmes applying TC 
principles (93 %) are longer-term. Where programmes provide 
facilities for on-site medically assisted detoxification (using 
methadone or buprenorphine), the length of the detoxification 
phase typically does not exceed 28 days.
Residential treatment is typically medium to long in duration, 
with the actual length varying according to individual 
requirements. However, it was reported that recent years have 
seen a decrease in the planned length of time in residential 
treatment in some European countries, through the evolution 
of treatment but also in response to financial pressures. 
Whereas some countries, such as Estonia, report no change to 
planned residential treatment duration, others (e.g. Latvia, 
Denmark, Germany, the UK) continue to see shortening of 
planned residential treatment programmes. In Denmark, most 
notably, planned courses of treatment of one to two years are 
rarely seen, if at all, according to national treatment experts. In 
The length of time in treatment has been found to be 
related to favourable post-treatment outcomes in studies 
of residential and outpatient settings and with clients 
dependent on opiates or cocaine (e.g. Gossop et al., 
2000; Moos et al., 2000).
Treatment outcomes tend to improve as retention 
increases from three months up to 12 to 24 months or 
more (Simpson, 1997; Simpson et al., 1999). Such 
findings have been used to support the concept of 
‘minimum retention thresholds’ for effective opiate 
treatment, often defined as 90 days for residential 
treatment (Simpson, 1981). Other studies have found a 
more linear relationship between the time spent in 
treatment and improved outcomes, with a stronger 
relationship between treatment duration and 
improvement for long-term residential treatment (Moos 
and Moos, 2003; Zhang et al., 2003). Clients from the UK’s 
National Treatment Outcome Research Study (NTORS) 
residential programmes who remained in treatment for 
longer periods of time achieved better one-year outcomes 
than those who left earlier, in terms of abstinence from 
opiates and stimulants, reduced injecting and reduced 
criminal behaviour (Gossop et al., 2000). The effect of 
time in treatment is confirmed after controlling for the 
influence of other potential predictive factors.
Duration of treatment: ‘minimum retention 
thresholds’




Detoxification is a medically supervised intervention to resolve 
withdrawal symptoms associated with chronic drug use, and 
is sometimes a prerequisite for initiating long-term 
abstinence-based residential treatment.
In most Member States, residential facilities provide on-site 
detoxification — from opiates, benzodiazepines and alcohol 
— and, in many cases, medicines are used during 
detoxification.
Evidence from the UK indicates significantly better outcomes 
when inpatient detoxification is followed up with residential 
treatment. Ghodse et al. (2002) reported significantly lower 
rates of relapse in clients completing detoxification when it 
was immediately followed by residential rehabilitation 
treatment than when this was not available. Therefore, there 
are grounds for assuming that the provision of detoxification 
and rehabilitation within the same treatment context would 
reduce the likelihood of treatment dropout between services.
In the UK, Meier et al. (2007), based on a national sample of 
87 residential treatment facilities, established that over 
one-third (39 %) offer medically assisted detoxification within 
their treatment programmes. Although there were no 
differences in treatment philosophies, residential treatment in 
facilities that offered detoxification were typically of shorter 
duration and reported offering more group work than 
residential treatment services that did not offer detoxification.
Opioids for substitution treatment
Substitution treatment refers to the treatment of drug 
dependence by prescription of a substitute drug with the goal 
of reducing or eliminating the use of a particular substance, or 
of reducing harm and negative social consequences. For this 
analysis, data were available for 25 countries. Of these, just 
under three-quarters (n = 18) report some availability of 
integrated pharmacological (opioid substitution) residential 
programmes, in which residents receive opioid substitution 
treatment for their heroin addiction and follow a structured 
therapeutic programme. Within the 18 countries reporting 
residential facilities that provide integrated opioid substitution 
treatment (OST), just over half (n = 10) indicated qualitatively 
the level of availability (acceptance) of this treatment within 
residential programmes; a further eight countries supplied 
quantitative data on the facilities offering continuation of OST 
to residents.
residential treatment programmes and continuing care. These 
areas are undergoing considerable change and development, 
yet are largely unexplored within the EMCDDA publications to 
date.
I Intake assessment
The intake assessment typically includes a number of areas 
(e.g. drug use, physical and mental health, family and social 
support) evaluated upon entry into a residential treatment 
programme. It is a way of gathering information about the 
individual in order to better treat them and engaging in a 
process that enables understanding of their readiness for 
change, problem and resource areas. In addition, the basic 
information can be augmented by some objective 
measurement. It is essential for treatment planning that the 
collected information from assessment be organised in a way 
that helps to establish a treatment plan.
I Treatment planning
Treatment plans span from intake assessment to continuing 
care planning and onward referral. They coordinate the range 
of interventions and supports (e.g. legal, educational, 
employment services) provided to an individual client. In 
essence, these documents typically outline what is expected 
of the client and what the programme will provide in return. 
They are formulated by the client and the residential treatment 
programme staff and are used to monitor and document 
treatment goals and accomplishments. Typically the treatment 
plan recognises that treatment may occur in different settings 
(residential as well as outpatient) over time and reinforces 











EMCDDA PAPERS I Residential treatment for drug use in Europe
12 / 31
The 18 countries in this analysis were subdivided into those 
with high availability of OST within residential treatment (e.g. 
Spain, Portugal, Luxembourg), where more than half of the 
residential treatment facilities in the country offer an 
integrated opioid substitution programme in a residential 
setting, and those with low availability (rare acceptance) (e.g. 
Hungary, Austria, Slovenia, Poland, Ireland, Malta), where 
fewer than half of the residential facilities admit clients who 
continue to receive prescribed opioids during their residential 
stay (Figure 4).
In the eight countries for which numerical data are available, 
the residential treatment facilities that are reported to offer 
integrated OST vary considerably (ranging from one in Poland 
to nearly all facilities in Spain).
Thus, although opioid substitution services are on offer to 
opioid-dependent clients in residential programmes in a 
number of European countries, the access to these services 
and the consequent uptake vary considerably. Because, 
traditionally, residential programmes, notably therapeutic 
communities and 12-step-based programmes, have had 
unfavourable views about substitution treatment and 
concerns that the use of substitution medicines by residents 
would pose a threat to the programme, valid questions arise 
about the consequences of treating clients in OST in 
residential settings. Consequently, there is an emerging 
science of integration that is beginning to explore the 
effectiveness of admitting opioid-dependent clients currently 
in substitution treatment in residential settings.
FIGURE 4
Availability of integrated opioid substitution within residential 
programmes in Europe, 2011
 High availability   Low availability   Not available   No data
Sorensen et al. (2009) assessed the outcomes of treating 
clients in OST in a residential therapeutic community. Based 
on a sample of 231 therapeutic community clients, the study 
compared the 24-month outcomes of methadone-maintained 
clients (n = 125) with opioid-dependent drug-free clients 
(n = 106). Regarding a number of outcomes, notably retention 
in treatment and illicit opioid use, methadone clients were 
found to fare as well as other opioid users in therapeutic 
community treatment.
Wider health interventions
There is a variation in the degree to which clients in 
residential treatment receive services for health conditions 
other than drug dependence, such as HIV or hepatitis C virus 
(HCV). In particular, whereas several countries report that 
residential treatment facilities have referral systems in place 
for testing clients for HCV or HIV, only a few (e.g. Greece, 
Lithuania, the UK) mention residential facilities that offer 
on-site HIV/HCV testing and vaccination (hepatitis A and B). 
No HIV or HCV treatment delivery is reported in residential 
treatment facilities in Europe. The reasons cited by national 
experts for not offering routine testing and vaccination 
include the lack of facilities for testing and/or medical 
personnel for treatment. For example, in Denmark, residential 
treatment is separated from the healthcare system, so 
residential programmes do not have the necessary resources 
to offer medical interventions. Organisational factors thus 
appear to influence the provision of on-site medical services 
to clients in residential treatment.
Drug users are at high risk of hepatitis C infection and also 
constitute a group that is medically underserved. Advances in 
the treatment of hepatitis C infection with direct antiviral agents 
and a growing evidence base for its effectiveness among drug 
users indicate the potential for extending strategies to treat 
hepatitis C among drug users. To be successful, these 
treatments include an emphasis on medication adherence and 
appropriate management of side effects — residential settings 
are uniquely situated to provide comprehensive treatment and 
monitoring.
Rosedale and Strauss (2010), based on an analysis of 
qualitative descriptive data from 20 clients in three 
residential drug treatment programmes, reported on what 
clients in residential treatment think about depression and 
the risks of neuropsychiatric side effects associated with 
interferon treatment for hepatitis C. The results emphasised 
that residential treatment programmes offer a unique 
opportunity to undergo antiviral treatment because they 
capitalise on clients’ heightened readiness for change. Along 
with that, clients’ perceived insufficient knowledge about 
hepatitis C among psychiatric staff and clients’ fear that 
hepatitis C side effects would sabotage addiction recovery 
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‘pillars’ of social reintegration are (i) housing, (ii) education 
and (iii) employment (including vocational training). Other 
measures, such as counselling and leisure activities, may also 
be used. Although recovery from drug use and rehabilitation 
of problem drug users (particularly in the traditional 
abstinence-oriented sense) are often focused on the 
relationship between an individual and drug use, social 
reintegration is also concerned with the position of the 
individual in wider society. Social reintegration interventions, 
including education, vocational skills training and 
employment-related interventions, are often an important 
element of residential treatment programmes. A recent 
EMCDDA Insights report provides fuller detail on the 
availability of these interventions in Europe and their 
effectiveness for drug users undergoing treatment including 
in residential settings (EMCDDA, 2012b).
were reported. The study concluded with a recommendation 
about increased hepatitis C-specific psychiatric education 
and staff training to facilitate better use of residential 
treatment programmes for treating hepatitis C. Consequently, 
a training programme for staff has been developed, 
employing a motivational approach, and is available to guide 
the treatment of hepatitis C-infected drug users in residential 
programmes (Strauss et al., 2007).
Social reintegration interventions
Although ‘social reintegration’ is not defined consistently 
across EU Member States, it is accepted as a foundation for 
drug treatment. As such, it includes all those activities that 
aim to develop human, social and economic capital. The three 
Opioid substitution treatment (OST) became widely 
available in Spain in the second half of the 1990s following 
a change in the Spanish legislation that lifted restrictions on 
prescribing methadone and gave rise to a dramatic increase 
in the number of heroin users entering this treatment. 
However, the use of substitution medicines in residential 
facilities (mainly therapeutic communities) did not occur 
until the late 1990s and the beginning of the 21st century, 
signifying a change in the then exclusively drug-free 
orientation and philosophy of these programmes.
According to 2012 data, about 67 500 opioid-dependent 
individuals receive substitution treatment in Spain. 
Although the majority (75–80 %) of clients receive this 
treatment in outpatient facilities, outreach programmes, 
pharmacies or prisons, about one-quarter receive 
substitution treatment in residential (traditionally drug-free) 
programmes. It is estimated that almost all residential 
facilities (a minimum of 90 %) offer continuation of OST to 
residents. Methadone is the most widely used medication.
Of the 131 residential facilities following the therapeutic 
community approach, about 90 % allow residents to benefit 
from OST. Of the 77 residential facilities applying cognitive–
behavioural therapy or other psychotherapy, one specialises 
in the treatment of cocaine users only and the remaining 76 
present no obstacle to clients who are in receipt of OST at 
the point of referral to residential treatment or wish to 
initiate OST while in residence.
Typically, therapeutic community residents who benefit 
from substitute medication are already engaging with an 
outpatient methadone prescriber at the time they are 
admitted into a therapeutic community. The safe dispensing 
of methadone prescriptions is carried out by available staff 
members at the therapeutic community, while the client is 
followed up by the outpatient facility’s professionals who 
initiated substitution treatment for the client. In some 
therapeutic communities, methadone is both prescribed 
and dispensed, contingent upon availability of appropriate 
professionals (medical doctors or nurses) who are also 
responsible for the follow-up of clients. In contrast, 
methadone is typically dispensed in a conveniently located 
outpatient facility for clients engaging in cognitive–
behavioural and other therapy programmes.
Some challenges for the future relate to (i) ageing users in 
OST programmes, who will require better coordination 
between health and social systems and services providers; 
(ii) remaining stigma attached to clients in OST, which will 
need to be resolved for the full acceptance of these 
individuals by all health and social service professionals 
and by society in general; (iii) broadening the range of 
substitute medicines, to include buprenorphine, 
buprenorphine–naloxone and others, available to clients in 
residential treatment, that is if their profile meets the 
required criteria, and independently of economic 
considerations about the cost of these medicines.
Integrated opioid substitution residential programmes in Spain
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Along with treatment and support, the above interventions 
may encourage adherence to antiretroviral medication and to 
promote general health, as well as providing a rapid and clear 
route back into structured treatment. Treatment systems 
ensure that referral pathways are in place, and residential 
treatment services have a rapid re-entry option.
Continuing care practices in Europe
In most Member States, many residential facilities offer a 
programme of aftercare or some form of therapeutic follow-up 
that is appropriate for individuals who need that level of 
support. Such programmes are reported to be of varying 
degrees of comprehensiveness.
The intensity and duration of care following a residential 
treatment episode depends upon the individual’s needs; 
available supports range from longer-term and self-contained 
therapeutic programmes (e.g. Luxembourg, France, Spain) to 
less supervised half-way and quarter-way houses (e.g. 
Hungary, Slovenia) from which individuals are transitioning 
back into the community. Reported practices typically relate 
to access to housing, employment and educational support in 
the community and linkage with support groups and mutual 
aid groups or peer support (e.g. Narcotics Anonymous (NA)).
In England, a joint review carried out by the NTA and the 
Healthcare Commission (now the Care Quality Commission) 
(NTA and Healthcare Commission, 2007) found that 88 % of 
inpatient and residential services had policies to enable 
service users to effectively integrate into the community and 
to provide appropriate aftercare following the service user’s 
exit. The NTA’s report on the role of residential rehabilitation in 
an integrated drug treatment system found that residential 
rehabilitation is not an automatic door from the treatment 
system but an integral part of a network of services, and the 
majority of residential rehabilitation clients return to 
community-based treatment services for further structured 
support afterwards. Out of the 164 drug or drug and alcohol 
residential rehabilitation services listed by Drink and Drug 
News (DDN, 2011), 85 units offer aftercare and 69 units offer 
resettlement.
I Continuing care
How should we define continuing care? It is extended contact 
and support beyond the formal end of the residential 
treatment episode. The period immediately after leaving 
residential treatment is one of high risk of relapse to drug use 
and increased overdose related mortality (Ravndal and 
Amundsen, 2009; Davoli et al., 2007). Promoting and ensuring 
care and support is one possible way to sustain treatment 
gains. 
Studies of continuing care following residential treatment (for 
a review, see McKay, 2009) suggest that the following may 
improve outcomes:
n  monthly contact for the first year of recovery, with 
adjustments as necessary (up or down according to the 
client’s level of functioning);
n  extended contact for years, rather than months;
n  availability of medications where necessary;
n  availability of treatment options of varying types and 
intensities, should the need arise.
Continuing care may be provided in a variety of different ways, 
ranging from contacts and check-ups to supported 
accommodation. For example:
n  the Contracts, Prompts and Reinforcement (CPR) 
intervention — a cognitive–behavioural approach designed 
to facilitate treatment and aftercare by maintaining clients’ 
continuing engagement with services (Lash and Blosser, 
1999; Lash et al., 2013);
n  telephone-based follow-up — a programme that, after an 
initial face-to-face session, uses weekly 15- to 20-minute 
telephone calls to provide counselling in conjunction with 
behaviour monitoring (McKay et al., 2004; McKay et al., 
2005a,b);
n  recovery management check-ups — regular phone calls to 
(or other contact with) people who have left residential 
treatment to facilitate early detection of relapse, reduce the 
time to treatment re-entry when necessary and improve 
long-term outcomes (Scott and Dennis, 2003, 2009, 2011);
n  Oxford Houses — abstinence support and accommodation 
in the community to former drug users who are willing to 
live together (Molloy, 1990; Jason et al., 2007).
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Countries with organisation at a regional level reported 
challenges to the maintenance of sufficient quality of nation-
wide referral processes to and from residential treatment and 
related collaborative arrangements. For instance, in Austria, 
such processes and arrangements are typically able to ensure 
clients’ moves from residential services to the community 
(and back) within one and the same region. However, as 
residential treatment facilities have national referral/
catchment areas, it is vital that optimal collaboration links be 
established and maintained between all relevant service 
providers across geographical regions.
These findings suggest that residential treatment in Europe 
should be seen as an integrated part of the network of 
services that form national drug treatment systems. The data 
show that residential treatment is not necessarily an ‘exit door’ 
from the treatment system and that, when clients complete 
their treatment at a residential facility, they frequently return 
to community-based structured support services from other 
parts of the system before they are ready to complete their 
drug treatment.
Impact of engagement with continuing care on 
treatment outcome
There is good evidence that participation in continuing care, 
including engagement with self-help groups, is important for 
sustained outcomes from treatments provided in residential 
settings.
In England, the National Treatment Outcome Research Study 
(NTORS), using a longitudinal, prospective cohort design, 
included 142 drug-dependent clients recruited at intake to 
residential treatment. It found that clients who attended 
mutual aid groups (e.g. NA) after treatment were more likely to 
be abstinent from opiates at follow-up, and more frequent NA 
attendees were more likely to be abstinent from opiates and 
alcohol than both non-attendees and infrequent (less than 
weekly) attendees (Gossop et al., 2008). The same conclusion 
about the beneficial effect of self-help group participation — 
in terms of increased abstinence rates at follow-up and 
reduced costs of continuing care — has been found in a 
number of studies, with a mixture of residential and outpatient 
attendees (e.g. Moos et al., 1999; Ritsher et al., 2002; 
Vederhus and Kristensen, 2006; Humphreys and Moos, 2007).
When treatment, employment and other support providers 
work in a unified way, clients are more likely to achieve their 
treatment and social goals. Each individual has distinct 
treatment and social needs, and providers need to work 
together closely to ensure that care planning is delivered in 
a seamless way.
In Norway, to ensure continuity of care for residential 
treatment clients, treatment and social services agree 
common referral and care pathways that make use of 
three-way review meetings to ensure that an integrated 
response to treatment and social needs is offered.
While the client is in residential treatment, a contact 
coordinator works with them in a range of domains, 
including participation in the Norwegian Labour and 
Welfare Organization qualification programme, assistance 
in finding accommodation, and domestic assistance and 
advice. The social services are notified in good time and 
with the client’s consent about the range of municipal social 
services that an individual client would use. The discharge 
from residential treatment is thus prepared in cooperation 
between the client, social services and the residential 
treatment facility.
Drug users in need of long-term coordinated services are 
also entitled to an individual plan. The plan is intended to be 
a tool for cooperation between the client and a range of 
social services providers in the community. Furthermore, it 
also contributes to strengthening coordination between the 
relevant service providers — health, education, employment 
sectors — to ensure that the clients gets the help they 
need. Finally, the individual plan that is drawn up for clients 
is supposed to ensure that the risk of relapse after a stay in 
a residential treatment programme is reduced.
Although the provision of the range of social and 
therapeutic follow-up services is predominantly a 
responsibility of the municipalities, such services are 
sometimes offered by the residential facilities as an integral 
part of long-term rehabilitation. The local authorities can 
collaborate with voluntary organisations in a partnership, 
but the service is usually anchored in the Social Services 
Act to ensure that the rules concerning correct processing 
of cases are adhered to and legal rights are protected.
Continuing care in residential treatment in the Norwegian context: a case study
EMCDDA PAPERS I Residential treatment for drug use in Europe
16 / 31
I 5. Residential treatment clients
This section looks at the profile of treatment clients in 
residential programmes and provides an overview of some 
specific groups of using clients targeted by residential 
treatment. In line with the TDI protocol and definitions (see 
box), this part of the paper uses the term ‘inpatient treatment’ 
instead of ‘residential treatment’.
I  Number of inpatient treatment clients in Europe in 2011
In the 22 European countries providing data, around 35 000 
drug clients entered inpatient treatment in 2011; 8 500 of 
these were entering for the first time. The number of clients 
entering inpatient treatment ranged from fewer than 300 
clients in Luxembourg, Cyprus and Hungary, through more 
than 2 000 in the Czech Republic, Sweden, the UK, Norway 
(2)  ‘Drug treatment is defined as an activity (activities) that directly targets 
people who have problems with their drug use and aims at achieving defined 
aims with regard to the alleviation and/or elimination of these problems, 
provided by experienced or accredited professionals, in the framework of 
recognised medical, psychological or social assistance practice’ (EMCDDA, 
2012d).
(3)  2011 data (n = 21: Belgium, Bulgaria, the Czech Republic, Denmark, Germany, 
Greece, France, Cyprus, Luxembourg, Hungary, the Netherlands, Austria, 
Ireland, Poland, Romania, Slovakia, Finland, the UK, Croatia, Turkey, Norway); 
2010 data (n = 1: Sweden).
(4) 2013 Statistical Bulletin — Tables TDI-7 and TDI-2.
The best available information source to describe the 
profile of drug clients entering residential treatment in 
Europe is the TDI; see Statistical bulletin (SB) (2). In line 
with  TDI protocol and definitions, this part of the paper 
uses the term ‘inpatient treatment’ instead of ‘residential 
treatment’.
Data are collected on six types of treatment centres/
programmes, including inpatient settings. The category 
‘inpatient setting’ refers to places ‘where the clients may 
stay overnight and include therapeutic communities, 
private clinics, units in hospital and centres that offer 
residential facilities’. This definition is broader than the 
definition of residential settings used for this paper, 
although the terms ‘inpatient’ and ‘residential’ treatment 
are used interchangeably. The structure of TDI data does 
not allow for disaggregation of inpatient detoxification 
and residential treatment data; this is one general caveat 
which needs to be understood when interpreting the 
analysis presented in this part of the paper.
Another issue that may affect this part of the analysis is 
that country differences in the profiles of inpatient clients 
may be related to differences in organisation at the 
national level of the drug treatment system, the role of the 
inpatient sector and data coverage of inpatient clients, 
besides actual country differences among clients.
For the present analysis on clients who enter inpatient 
treatment, data were available from 22 countries (3). It 
should be noted that, in six EU countries not reporting 
inpatient data (4), the inpatient treatment is likely to play an 
important role in the national drug treatment, through 
either the system of therapeutic communities (Spain, Italy, 
Portugal and Slovenia) or the drug units in psychiatric 
hospitals (Latvia and Lithuania). Therefore, the European 
picture of inpatient treatment clients that is beginning to 
emerge should be taken with caution. In two countries 
(Estonia and Malta), all data on clients entering drug 
treatment are reported without a breakdown by the type 
of treatment centre and so could not be included in the 
analysis.
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(1) 2010 data.
FIGURE 5
Drug users entering inpatient treatment in 2011, or the most 
recent year available, in 20 EU countries, Turkey and Norway
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TABLE 2
Number of clients entering specialist outpatient and inpatient 
treatment in 20 Member States in 2011 and the percentage 
of all clients entering inpatient treatment
Country Inpatient Outpatient Inpatient %
Luxembourg 128 35 79
Romania 984 758 56
Czech Republic 2 334 2 025 54
Slovakia 865 774 53
Sweden (1) 2 606 2 549 51
Poland 550 792 41
Norway 3 921 4 896 44
Finland 535 908 37
Austria 1 526 3 037 33
Belgium 1 339 3 192 30
Greece 1 576 4 258 27
Bulgaria 394 1 584 20
Ireland 1 197 5 359 18
Cyprus 156 814 16
Netherlands 1 768 11 341 13
Germany 8 050 60 169 12
Croatia 563 7 102 7
Hungary 299 3 740 7
Denmark 214 5 472 4
United Kingdom 3 734 112 108 3
France 774 45 247 2
Total 31 745 (2) 264 450 (3) 11
Notes:
(1) 2010 data.
(2)  More than 50 % of all inpatient clients are reported by the Czech Republic, 
Norway, Sweden, Austria, Belgium, Greece, Ireland, Germany and the UK.
(3)  More than 50 % of all outpatient clients are reported by Greece, Ireland, 
Germany, Denmark, France, the UK and Norway.
I  Characteristics of treatment clients in Europe in 2011: inpatient versus outpatient
This section describes clients entering inpatient treatment in 
2011, with a focus on a number of sociodemographic features 
and patterns of drug use, and also includes a comparison with 
the profile of outpatient treatment entrants (8).
(8)  The comparison includes data from 20 countries where data on both inpatient 
and outpatient treatment settings were available (2011 data, n = 19 countries: 
Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Greece, France, 
Cyprus, Luxembourg, Hungary, Austria, Romania, Slovakia, Finland, Ireland, 
Poland, the UK, Croatia, Norway; 2010 data, n = 1 country: Sweden). A number 
of differences were identified and these are shown in Appendix 2. Two 
countries reporting inpatient data are excluded: Turkey, which reports data 
only on inpatient clients, and the Netherlands, which does not disaggregate 
inpatient and outpatient data.
and Turkey, to about 8 000 inpatient clients reported by 
Germany (5) (Figure 5).
Inpatient clients as a proportion of all treatment clients
Drug clients entering inpatient centres represent only a small 
proportion of all reported drug clients; in 2011 they were 
around 11 % of all reported drug clients in Europe (7 % among 
new clients) (6) (7). The proportion reported to enter inpatient 
treatment varies by country (from 2 % in France to 79 % in 
Luxembourg). Those differences may be partly the result of 
variations in data coverage, ranging from 14 % to 100 % of 
existing inpatient units in the country, and resulting in an 
average of around 60 % of inpatient units in Europe being 
covered in data collection.
Data from 20 countries in 2011 show that, on average, one 
person commences inpatient treatment for every 11 people 
starting specialist outpatient treatment. However, substantial 
inter-country differences exist. Equal demand for both 
modalities is reported in five countries — the Czech Republic, 
Romania, Slovakia, Sweden and Norway — with between 40 % 
and 60 % of all treatment demands being for either outpatient 
or inpatient treatment. Eight countries (Belgium, Greece, 
Bulgaria, Ireland, Cyprus, Austria, Poland and Finland) 
reported that between 15 % and 40 % of all treatment demand 
was for inpatient treatment. In contrast, Denmark, France, 
Hungary, Croatia and the UK reported that fewer than 15 % of 
all demands were for inpatient treatment, indicating that 
residential treatment may play a lesser role in these countries. 
Possible reasons could be costs or geographic conditions (low 
population density tends to correlate with low availability of 
specialised services), but traditions and general 
characteristics of the healthcare system could also be factors 
(Table 2).
(5) 2013 Statistical Bulletin — Table TDI-7.
(6)  This description is based on data from 20 countries for which data on both 
inpatient and outpatient treatment clients were available (2011 data, n = 19 
countries: Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Greece, 
France, Cyprus, Luxembourg, Hungary, Austria, Poland, Sweden, Romania, 
Slovakia, Finland, the UK, Croatia, Norway; 2010 data, n = 1 country: Ireland). 
Two countries reporting inpatient data are excluded: Turkey, which reports 
data only on inpatient clients, and the Netherlands, which does not 
disaggregate inpatient and outpatient data.
(7) 2013 Statistical Bulletin — Table TDI-1.
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Member States (e.g. Belgium, the Czech Republic, Spain, Italy, 
Portugal, Slovenia, Finland, the UK), residential programmes 
are viewed on a continuum depending on how suited (e.g. in 
terms of medical staff available, appropriate certification of 
the programme) they are to serve drug-dependent clients who 
also suffer from a mental illness. (For reviews of research on 
residential programmes for people with severe mental illness 
and co-occurring substance use disorder, see Brunette et al., 
2004; Drake et al., 2004.)
Specialised residential programmes specifically tailored to the 
needs of women and/or women and families with children 
exist in a number of countries (e.g. Belgium, Bulgaria, 
Germany, the Czech Republic, Ireland, Greece, Spain, France, 
Italy, the Netherlands, Portugal, Slovenia, Finland, the UK, 
Norway). In addition, some general programmes have been 
augmented with special groups that discuss women’s issues, 
as well as individual and group counselling (for additional 
information, see Selected issue on Pregnancy, childcare and 
family: key issues for Europe’s response to drugs, EMCDDA 
2012c).
Older drug users represent a growing proportion of drug 
treatment demand, including in residential settings (EMCDDA, 
2010). Whereas some countries (e.g. the Netherlands) report 
residential treatment programmes that cater for the needs of 
this ever-growing population of drug users, treatment experts 
in other countries (e.g. Spain) report that suitable (long-term) 
residential programmes that offer care and support to chronic, 
ageing drug users are yet to be fully developed.
Modifications to residential programmes to meet the 
treatment needs of migrant drug users exist in Germany, 
Spain and Greece, and some Member States report 
refocusing of existing facilities and therapeutic tools or 
establishing new residential programmes to address the 
needs of individuals with behavioural addictions such as 
gambling (e.g. Bulgaria, Italy, Ireland).
In a number of countries (e.g. Hungary), although residential 
treatment facilities are reported to be open to drug users with 
a range of needs, residential services are not specifically 
tailored for particular groups; rather, provision for specific 
subgroups of clients is provided within an universal treatment 
framework. In a time of constrained fiscal resources, this 
approach, with no separation of residential services according 
to specific client groups, is being increasingly seen as an 
attractive mechanism for efficient resource use. For instance, 
in Spain, although experts in the country agree on the need for 
specialised services for certain client groups, such as the 
dually diagnosed, there is a growing emphasis on a serve-all 
approach and in some autonomous communities there are an 
increasing number of examples of residential treatment 
catering for all client groups.
Age and gender
Inpatient clients are reported to be slightly older (32 years) 
than outpatient clients (31 years) at treatment entry, although 
variations are reported by drug and by country. The biggest 
difference is seen among cannabis treatment clients 
(inpatient 27 years vs. outpatient 25 years). For those with 
primary opioid-use problems, inpatient clients were slightly 
younger (34 years) than outpatient heroin clients (35 years).
The social circumstances of clients varied between treatment 
settings and are generally more disadvantageous for inpatient 
than outpatient clients. Higher proportions of inpatient 
treatment entrants reportedly have no schooling or a basic 
level of education (inpatient 31 % vs. outpatient 22 %), are 
unemployed (inpatient 61 % vs. outpatient 48 %) and live in 
unstable accommodation (inpatient 16 % vs. outpatient 10 %).
Patterns of drug use
A higher proportion of primary users of amphetamines is 
noted in inpatient treatment (16 %) than outpatient treatment 
(6 %). Overall, clients entering inpatient treatment tend to have 
more precarious patterns of drug use, as shown by the higher 
proportions reporting injecting as the main route of 
administration for the primary drug for which they enter 
treatment (inpatient 22 % vs. outpatient 18 %) (Appendix 2).
I Clients targeted in specialised residential treatment
Some countries provide specialised residential treatment 
tailored to the needs of specific subgroups of clients, including 
adolescents, people with dual diagnoses, and women and/or 
families with children, as well as other client groups.
Modifications to residential programmes to meet the 
treatment needs of young people are available in some 
Member States (e.g. Germany, Estonia, Ireland, Greece, 
France, Spain, the Netherlands, Portugal, Finland). These 
programmes vary in the treatment they provide. Nonetheless, 
common features include varying degrees of family 
involvement in the treatment and in the process prior to 
discharge and the availability of aftercare support for young 
people and their families. Typically, treatment for this specific 
group is reported to focus a lot more on personal plans and 
personal development than on drug dependence. As with 
other client groups, because each young person has unique 
issues and needs, programmes determine what is in the best 
interest of each individual before making treatment decisions 
(for more information, see Fournier and Levy, 2006).
Residential programmes with a special treatment focus on 
dual diagnoses are rarely reported. However, in a number of 
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n  local bodies and private sources (Spain, Sweden);
n  local bodies, health insurance and private sources (the 
Netherlands);
n  health insurance and private sources (Belgium, Slovenia);
n  private sources (Bulgaria, Greece, Cyprus, Malta).
There are 11 countries where there is no central government 
involvement. Local bodies account for all residential treatment 
funding in Denmark, Italy and Finland, whereas local or 
regional bodies finance residential treatment in combination 
with funding from health insurance in the Czech Republic.
Funding of residential treatment by health insurance is 
reported by seven countries. In three of these (Germany, 
France and Luxembourg), health insurance is the sole funder, 
whereas it is a supplementary source in four others (Belgium, 
the Czech Republic, the Netherlands and Slovenia). The 
existence of private sources of funds is reported by nine 
countries (Table 3).
In the financing dimension, the proportion of residential 
treatment budget as a percentage of the overall drug 
treatment budget is an important indicator for describing drug 
treatment systems. An earlier analysis of 2009 data that 
includes three countries (the Czech Republic, Germany and 
Luxembourg) indicates that, in each of the different countries, 
residential treatment consumes a different share of the total 
allocation of drug treatment resources, ranging between 8 % 
(Germany) and 43 % (the Czech Republic) (EMCDDA, 2011).
Beyond the examination of funding allocation for residential 
treatment, unit costs, typically presented in treatment studies 
as the daily cost of providing a client with a particular sort of 
treatment, are a crucial indicator for characterising residential 
I 6.  Organisational structure of residential treatment
This part of the paper examines the organisational structures 
of residential treatment, that is non-therapeutic attributes that 
may influence the treatment approach and the types of 
services provided to clients (Durkin, 2002). Structural aspects 
of treatment facilities include financing arrangements and 
management, ownership and quality management (Heinrich 
and Lynn, 2002; Olmstead and Sindelar, 2004).
I Financing and costs
First, we review the main payers or funders of residential 
treatment services in Europe, before moving on to examine 
ownership and programme accreditation. Depending on the 
country, the funders of drug treatment services can include 
public sources, private sources and social health insurance.
When using the term ‘public sources’, we mean funds raised by 
governments through taxes, donor grants and loans (Schieber 
and Akiko, 1997). These sources are operated and managed at 
different administrative levels, from national to regional or local. 
In a number of European countries, healthcare is financed 
through health insurance, whereby workers and employers are 
obliged to contribute to health insurance funds which also 
finance drug treatment. Health insurance programmes may also 
receive government funds for unemployed individuals and other 
groups that are eligible for subsidised contributions. Other 
sources include donors, either international or domestic, 
financing drug treatment through grants, loans and in-kind 
contributions, as well as individuals who pay out-of-pocket fees 
directly to providers of residential treatment services.
In some comparative studies, the mode of financing is taken as 
the main or even sole indicator for describing healthcare 
systems. It is clearly important for clients’ access to services 
whether they are entitled to healthcare on the basis of 
earmarked social insurance contributions or citizenship (which, 
in general, means tax financing) or it is necessary for them to 
make the payment privately (Mossialos and Thomson, 2003).
In Europe, governments are crucial payers for residential 
treatment in 21 of the 23 reporting countries (Table 3). The 
roles played by the various levels of government, however, 
differ between countries. In Poland and Portugal, residential 
treatment funding is provided solely by the central 
government. In 14 further cases, the central government 
provides a proportion of the funding for residential treatment, 
in a joint financing arrangement with:
n  local bodies (Estonia, Lithuania, Hungary, the UK);
n  local bodies and health insurance (Austria);
TABLE 3
























































Source: Reitox national focal points.
Notes:
(1) Health insurance includes both health and pension funds.
(2) Public funding includes welfare funds or social budgets.
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n  government, which breaks down into
– state/federal,
– local/regional;
n private, for profit;
n private, non-profit.
In all of the countries in Europe, the public sector (i.e. 
governments, state, local or both), shares a varying degree of 
ownership of residential treatment provision. Spain, Austria, 
Finland, Sweden and Portugal report ownership of residential 
treatment by private, for-profit, entities. Although a number of 
countries (e.g. Bulgaria, Greece, Austria, Luxembourg, Finland, 
Spain, Sweden, Romania, the UK) report that the responsibility 
for the operation of some residential treatment facilities lies 
with private non-profit organisations (also known as non-
governmental organisations (NGOs), as the vast majority of 
NGOs are non-profit), relevant data are limited.
Nonetheless, in Austria, it can be established that, of the 24 
reported residential facilities, the legal structure behind 21 % 
is an NGO. In Sweden, the distribution of publicly operated 
and private for-profit companies is almost equal, 40 % and 
42 % respectively, whereas NGOs own the remaining 18 % of 
residential treatment facilities.
The picture, however, is more complex, as there is 
subcontracting of the provision of residential treatment 
services (along with clinical staff training and working with the 
local community) by governments to NGOs. In some cases 
(e.g. in Spain and Italy), religious entities manage residential 
treatment facilities on behalf of the state.
Although NGOs in Europe have a history of commitment to 
addressing the treatment and rehabilitation needs of drug 
users, this has been predominantly done through granted 
subsidies. Recent years, however, have seen formal 
subcontracting of residential treatment services to NGOs 
becoming a prominent and common arrangement. For 
example, in Spain, in order to ensure transparency and equity 
in the dispersion through NGOs of public money for residential 
drug treatment, the government agency for control and 
intervention systems has installed a mechanism whereby, akin 
to the participation regulation of the private sector in providing 
public services, NGO-provided residential drug treatment 
services are purchased by government agencies in a context 
of competition and bidding. Similar arrangements can also be 
observed in the UK.
Commentators on international NGOs note that present-day 
NGOs are often legal corporations with full-time staff and 
governing boards; their organisational structures are more 
formal and complex and their operations are more strategic 
and business-like (Breslow, 2002). Although continuing 
support from governments and collaborative relationships 
between NGOs and governmental organisations may be 
treatment. Treatment interventions and the level of 
professional staff involvement are among the factors that have 
an impact on unit costs. Although the examination of 
residential treatment costs, as a simple costing of treatment 
exercise or in the context of an economic analysis of the 
cost–benefit variety, is crucial to determine if and how 
(long-term) residential treatments fit the present global public 
spending cut plan, the data available for unit costing are very 
limited. Based on data from three national focal points, 
residential treatment per client per day was estimated to 
range from EUR 31 (9) (Hungary) through EUR 107 (10) (the 
UK) to EUR 622 (Cyprus) (year of reference: 2011).
Regarding access to residential treatment providers, the share 
of public funding indicates the extent to which it is considered 
a public responsibility to guarantee entry for those who require 
drug treatment in a residential setting. For the individual client, 
another indicator of the financing dimension is the level of 
private out-of-pocket payments. In the general health field, a 
number of studies have shown how private cost sharing 
reduces health service utilisation and increases inequality (e.g. 
Thomson and Mossialos, 2004; Van Doorslaer et al., 2006).
Of the nine countries that indicate that residents (and/or their 
families) contribute financially to residential treatment, the 
Netherlands, Spain, Slovenia and Portugal provide data. In the 
Netherlands, since 2012, in some cases, clients are required to 
pay contributions of EUR 5 per day (EUR 145 per month). 
However, there are no full monthly cost data to estimate clients’ 
contributions as a proportion of the total monthly residential 
treatment fee. There are groups of clients in residence in the 
Netherlands that are exempt from fees. These groups include (i) 
young persons (17 years of age or less), (ii) clients who are 
compulsorily placed in residential treatment and (iii) crisis 
admissions. In Spain, a client’s financial contribution to 
residential treatment typically constitutes a small proportion of 
the total cost of the treatment episode. Typically, a client’s 
contribution ranges between EUR 7 and EUR 27 per day 
(EUR 200 and EUR 800 per month respectively), although there 
are cases where clients bear the total cost of their residential 
treatment. In private residential facilities in Spain, monthly fees 
of between EUR 1 000 and EUR 5 000 are paid in full by 
residents. In Slovenia, clients in residential treatment 
programmes pay up to 20 % of the total treatment fee.
I Type of ownership
The type of ownership indicates the type of entity responsible 
for the operation of the residential facility. Data suggest that, 
in Europe, residential facilities fall into three categories:
(9)  Maximum base funding that can be requested for the treatment of a client per 
day in residential settings.
(10) Costs are considerably higher when detoxification is included.
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standards elaborate on the concept of human rights, with 
emphasis on respect and transparency of philosophy goals 
and regulations. They are aimed at providing ‘maximum 
opportunity for physical, spiritual, emotional and aesthetic 
development’ of clients and carer (11). The practical aspects 
covered by the standards include training and supervision of 
staff and accountability to an external executive or community 
board.
Almost all the reporting countries mention some form of 
public authorisation of residential treatment facilities. The 
relevant guiding requirements are set by legal documents 
which can refer to national guidelines.
Guidelines specifically targeting therapeutic communities are 
available in Bulgaria, Cyprus and Portugal. In other countries, 
residential facilities may adopt guidelines which are broader in 
scope, as is the case in Germany, France, Slovakia, Finland, 
Sweden, the UK and Norway. The Bulgarian guidelines, 
published in 2009, include concepts, aims and a normative 
framework of psychosocial rehabilitation (including residential 
programmes), the criteria for monitoring and assessment, 
basic ethical principles and definition of an ethics charter for 
the staff. The Portuguese guidelines focus on the promotion of 
integration among public sector and private therapeutic 
communities, synthesise the legal instruments scattered 
among many different documents and describe the activities 
of the responsible body for the coordination of rehabilitation 
facilities. Compliance with the national guidelines for 
residential treatment is also mandatory in Cyprus.
Service standards, staffing levels and minimum 
requirements for staff qualifications
Standards applied to therapeutic communities are reported by 
at least 18 countries (12). These standards can be developed 
nationally or locally and others emanate from international 
certification agencies (such as International Organization for 
Standardization (ISO) 9000 or the European Foundation for 
Quality Management; for more detail, see http://www.
emcdda.europa.eu/best-practice/standards/treatment).
Most European countries provide some indication about the 
educational background required to work in a therapeutic 
community. Typically, psychiatrists and other medical 
specialties including nurses, psychologists and social workers 
are mentioned. In Bulgaria, the conditions under which former 
drug users can be employed in a therapeutic community are 
defined and, in Greece, there are training programmes for 
ex-users who are considered ‘special therapists’. In Germany, 
(11) http://www.wftc.org/standards.html
(12)  Portugal, Finland, Germany, Slovakia, the UK, Spain, Denmark, Greece, the 
Netherlands, Belgium, Luxembourg, Malta, Poland, Romania, the Czech 
Republic, Estonia, Ireland and Lithuania.
strengthening NGOs’ capacities, recent accounts from Spain 
suggest that, in some few cases, NGOs may be perceived as 
lacking a commitment to public interest, a strong professional 
profile and suitable management. Nonetheless, in other cases, 
they are perceived as innovative, flexible and readily adaptable 
to changes and composed of committed individuals.
I Quality management
Quality of treatment across the European countries is ensured 
by applying evidence-based guidelines and finding a 
consensus on standards. Accreditation systems based on 
external evaluations are in place and, in some cases, access to 
funding is linked to quality assessment. As in many other fields 
of interventions in drug demand reduction, European 
countries put in place a variety of different approaches. Efforts 
to learn from each other and fasten the achievement of 
harmonisation are also undertaken.
Availability and adherence to guidelines
Figure 6 highlights the availability of instruments for quality 
management in residential treatment in Europe.
Quality tools for residential treatment have been developed by 
some international organisations, such as the World 
Federation of Therapeutic Communities (WFTC), which 
requires its members to respect eight standards. These 
FIGURE 6
Quality management in residential treatment programmes in 
Europe
 Guidelines+standards   Guidelines   Standards   Other
 No data
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Programme outcome documentation and evaluation
Evaluation of residential treatment programmes for use by 
providers to improve their programmes can consist of 
assessing activity such as referrals, bed or occupancy rates, 
programme retention, average duration of stay, existence of 
treatment plans and referral rates to continuing support and 
care. These can be evaluated by comparing standards (set by 
the programme itself or funders and/or accreditors) with 
actual practice. Such measures will be available in every 
programme and require little additional resource. In addition, 
client treatment expectation and satisfaction surveys and 
focus groups are useful in providing feedback from the 
resident and their family.
Activities related to outcome evaluation are reported by 15 
countries (14) with noticeable differences in the 
implementation. In some cases, these are systematically 
performed at the service or central level or they can be 
performed as occasional studies by external bodies. In 
Lithuania, quality evaluation is delegated to audit groups 
created within the services. These groups are expected to 
develop procedures and protocols and to set target indicators. 
They also need to design processes to deal with complaints by 
patients and initiate inquiries into the quality of services. In 
Germany, monitoring and evaluation of the health system is 
performed at the central level. Approximately half of all the 
inpatient facilities for people with substance-related 
disorders, eating disorders and pathological gambling 
behaviour provide statistical data to the ‘Deutsche 
Kerndatensatz’ (KDS) (German Core Data Set). Furthermore, 
rehabilitation services are compelled to submit detailed 
reports on their activities following some specific guidelines.
Recent examples of the use of evaluation systems to develop 
practice are reported by Austria and Poland. In Austria, for 
instance, the Carina treatment unit has regularly performed 
evaluation studies, in which some critical points were 
identified. These were the lack of adoption of evidence-based 
guidelines and the length of waiting times. Of particular 
interest is the analysis of the reasons for patient dropout. The 
largest number of dropouts were registered shortly after the 
start of treatment, typically owing to family relations, cravings 
for drugs and emotional instability, especially among the 
younger clients. In Poland in 2010, the Helsinki Foundation for 
Human Rights published a report on monitoring clients’ rights 
in drug treatment centres. On the basis of the report, the 
Ministry of Health proposed the formal adoption of the 
existing standards to improve the protection of clients’ rights.
(14)  Spain, Austria, Slovenia, Bulgaria, Denmark, Germany, Greece, the 
Netherlands, Slovakia, the UK, Cyprus, Belgium, Malta, Romania and the 
Czech Republic.
other professions such as physiotherapists or vocational 
therapists are mentioned and clear restrictions to the 
employment of not specifically qualified professionals are 
included in the guidelines set by the Pension Insurance 
Association. Germany is also one of the countries, along with 
Bulgaria, Finland and Portugal, which report a predefined 
minimum staff level. In Lithuania, the competences of 
psychiatrists and nurses are determined by the Ministry of 
Health, which also requires that licensed health practitioners 
renew their licence for practice every five years; this was 
recently extended to social workers.
The systematic inclusion of client perspectives as quality 
criteria is described by the Portuguese, Bulgarian, Spanish, 
German and Luxembourgish reports. In the Netherlands, the 
use of the Consumer Quality Index (CQ-I) became mandatory 
for the institutes for mental healthcare and addiction in 2012. 
This index includes questions about patient experiences with 
the information on treatment they received, the attitude of the 
caregivers, the available treatment options and the 
satisfaction with treatment. The data can be used, for 
example, by the managers of addiction care organisations to 
improve their care and by insurers to monitor the patient 
experiences at the facilities they contracted. The addiction 
care organisations were obliged to use the CQ-I 
questionnaires in a sample of their clientele. These 
questionnaires were created under supervision of the 
programme ‘Visible care’ (Zichtbare zorg), which was 
established in 2007 by the Ministry of Health, Welfare and 
Sport. There were plans that these activities would be taken 
over by a new Quality Institute in 2013, but it is not yet clear if 
or how the measurements will continue.
An accreditation system based on external evaluation 
constitutes the main approach in the Czech Republic, where 
sets of standards are in place for each type of intervention, 
including the therapeutic communities. Independent and 
qualified supervision provided by personnel trained under the 
international aegis of the European Association for 
Supervision (EAS) (13) is a central feature of the Czech quality 
system. In the UK, healthcare and social care are 
decentralised responsibilities, so that each of the four 
countries (England, Northern Ireland, Scotland and Wales) has 
a different regulatory body in charge of quality control. The 
principles around which those systems are created differ, but 
all include ethical issues, guarantees about the individuals 
providing the interventions (in England, a criminal record 
check is also requested), the appropriate promotion of health 
and well-being of patients and the accountability of the 
organisation.
(13) http://www.easc-online.eu/
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quality. In Lithuania, the facilities funded from the state or 
municipal budgets are not bound to respect quality criteria. In 
contrast, the therapeutic communities funded by the 
European Social Fund need to fulfil the criteria set by this 
agency.
In France, there is a mixed local–central system in which 
residential facilities have to submit a detailed annual report to 
the territorial delegation of the regional health agency to 
justify the use of the budget. At a national level, ‘RECAP’ 
(Recueil commun sur les addictions et les prises en charge 
(Common Data Collection on Addictions and Treatments)) 
collects these data for evaluation.
In Germany, where quality criteria are set by the pension 
insurance companies, the link with reimbursement is clearer, 
whereas in Malta, Cyprus, Portugal and Slovenia performance 
reports are evaluated by the ministries responsible for 
funding. In contrast, in two other countries — Croatia and 
Hungary — regulations and legal acts are reported to set the 
link between therapeutic performance and financing.
I 7. Conclusions
The history of residential treatment provides some insights 
into the development of drug treatment per se, as, in most 
countries, the first type of treatment offered to drug users was 
in residential settings.
Residential treatment programmes provide a multidisciplinary 
approach to enable drug-dependent individuals to gain control 
over their drug use and to achieve and maintain improvements 
in health, social and lifestyle domains. Psychosocial and 
pharmacological services are provided as part of a structured 
therapeutic process that begins with the withdrawal/
detoxification process and extends to aftercare planning 
following a residential treatment episode.
Although, historically, residential treatment programmes have 
been exclusively drug free, our data indicate that the 
importance of providing medication to substitute for the use 
of illicit drugs is coming to be appreciated as an essential part 
of treatment. This requires additional medical staff capacity to 
ensure that clinical guidelines, in relation to medication 
prescription, are adhered to. The peer community is a 
powerful tool that can be employed to support and monitor 
medication adherence and encourage dose reduction.
The combination of psychosocial and pharmacological 
interventions is congruent with the idea that addiction is a 
persistent condition that requires medication to improve 
functioning (McLellan et al., 2000). From this perspective, 
pragmatic and science-based interventions are the solutions 
Examples of systemic approaches to learning from errors are 
the clinical governance and error management approaches 
that are ongoing in England and Germany. In England, all 
providers are expected to designate a clinical governance lead 
in their service according to the guidelines of the National 
Institute on Drug Abuse (NIDA, 2012). The four main pillars of 
clinical governance have been incorporated by the World 
Health Organization (WHO, 2013): professional performance 
(technical quality), resource use (efficiency), risk management 
(the risk of injury or illness associated with the service 
provided) and clients’ satisfaction with the service provided. 
Clinical governance is a holistic approach to evidence and 
good practice, which encompasses each component of a 
service provider, including patients’ opinions, in a continuous 
process of improvement (Scally and Donaldson, 1998).
Links between financing and quality assurance
In recent years, residential facilities for drug treatment have 
faced growing pressure to monitor outcomes. Interest in the 
monitoring of outcomes has, in some cases, coincided with 
concerns about the quality of treatment and care in these 
facilities and sparked debate over the appropriate role of 
residential treatment in drug treatment systems that are 
dominated by community-based services. At the same time, 
leaders in the field of residential treatment have adopted a set 
of core principles to guide the delivery of residential 
treatment. Among these principles is the expectation that 
residential facilities measure outcomes that can be used to 
inform the development of quality improvement efforts and to 
demonstrate the value of residential treatment to families and 
other stakeholders.
A number of European countries (15) report that some form of 
relationship exists between funding and quality assurance. In 
some cases, activity ensuring reciprocity between the quality 
of treatment services, as measured by an external body, and 
the funding allocated to the service is undertaken at a local 
level, and only in a few countries are systems to link funding 
with quality control centrally implemented.
Some Spanish communities, for example, include 
standardised quality criteria (such as ISO 9000) as a 
prerequisite for granting subsidies. In the autonomous 
community of Valencia, a quality accreditation process took 
place in 2011 through a public institute operating under the 
Ministry of Health. Finland is another country where quality 
assessment is mainly performed in the context of local 
benchmarking. In the tenders for outsourcing service 
providers, public bodies insert exclusion criteria based on 
(15)  Spain, Slovenia, Portugal, Finland, Sweden, Denmark, the Netherlands, the 
UK, France, Cyprus, Italy, Luxembourg, Poland, Romania and the Czech 
Republic.
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to websites with databases. However, the approach chosen is 
descriptive, and thus the paper provides a mosaic of historical 
accounts; availability of residential drug treatment, including 
for specific client groups; reviews of current national 
discussions about residential treatment; and areas of 
achievement, opportunity and challenge.
In taking this forward, increased data collection, monitoring 
and residential treatment evaluations applicable across 
national frontiers would be fruitful. If such data collection and 
monitoring can be combined with national drug service 
frameworks or programmes, this could take quality assurance 
in (residential) drug treatment delivery in Europe a step 
forward.
It should be added that, although in this paper we consider 
residential treatment provision from European and national 
perspectives and talk about ‘the Danish’ or ‘the German’ 
experience, regional variations can be wide and therefore 
comparative analyses can be more meaningful when they are 
performed between regions, as well as across national 
frontiers. Therefore, future monitoring of (residential) drug 
treatment provision can include measures at both national 
and regional levels.
In an ‘age of austerity’ with shrinking treatment budgets in 
Europe (and beyond), the question is how residential 
treatment programmes need to develop and how they can 
target areas where they can make the most impact and 
achieve the most good at an acceptable cost. This is likely to 
mean demonstrating that they can engage effectively with a 
range of target groups, including, but not limited to, polydrug 
users, users of stimulant drugs for whom no efficacious 
pharmacotherapy is available, opioid users who may not be 
able to benefit from substitution treatment in the community, 
and people with non-substance addictions such as gambling. 
It is difficult to predict what the future holds for residential 
treatments. However, as these programmes are more 
resource-intensive and costly than outpatient alternatives, to 
respond to cost-saving demands, they are likely to continue 
developing and defining themselves as generic programmes 
that are able to provide a range of interventions, which may 
have the benefit of improved links with community services. 
Coupled with this, we are likely to see shorter programmes, 
quasi-residential choices and an increasing focus on tailoring 
residential treatment programmes to the needs of stimulant 
users for whom there is no effective pharmacotherapy. Finally, 
to ensure the continued contribution of the residential 
treatment component in national addiction services systems 
across Europe, improving the amount of information on quality 
assurance, monitoring and treatment effectiveness is likely to 
be of great importance.
emphasised, not necessarily based on what is ‘correct’ from a 
given ideological perspective.
The development and implementation of evidence-based 
clinical guidelines and service standards can play an 
important role in quality assurance and improving processes 
in residential treatment. However, it should be noted that the 
nature of standards and guidelines for complex 
psychotherapy-based approaches may differ from those being 
developed and implemented for medical-based treatments 
(e.g. opioid substitution treatment), in that the former are likely 
to be less operational and directive. Nonetheless, a 
considerable number of countries note the existence and use 
of such documents, with critical implications for maintaining a 
culture of accountability, ensuring quality and consistency of 
service provision and informing uniform staff training models.
This review shows that residential programmes are a mixture 
of services reflecting the philosophy of one or more treatment 
approach. It is beyond the scope of this paper to establish the 
extent to which current residential treatment networks (as 
part of overall drug treatment systems) are a result of ad hoc 
responses and adjustments or how far planning and 
coordination have guided their development in different 
countries. European countries can benefit from a systematic 
need assessment and exploration of the ways in which 
integration of treatment components in residential and 
outpatient settings can be delivered to yield added value to 
compensate for additional financial investment. The value will 
need to be examined at the level of the individual, their family 
and society at large, as well as accounting for clients’ 
subjective views of their treatment experience and 
satisfaction as a recognised marker of adherence to clinical 
standards.
The current way of providing residential treatment involves 
rethinking the timeframes within which people stay in 
residential treatment. Speculatively, the question is whether 
there is a trend to shorten the planned duration of treatment, 
coupled with a widespread development and expansion of 
adjunct outpatient and aftercare services by residential 
facilities. These adjunct programmes have been established in 
recognition of the need to provide some continuity between 
the residential and community environments. A related notion 
is the recognition that, although behaviour change can occur 
within the treatment milieu, the change is not necessarily 
transferable when people return to their families and 
communities.
One of the strengths of this paper is the variety of sources 
used, such as national or regional healthcare statistics, 
government reports, national surveys, scientific papers 
published in national or international journals and references 
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I Appendix 1














Belgium 14 8 0 17 0 0 31
Bulgaria 2 3 3 10 5 0 20
Czech Republic 18 (2) 10 0 15 0 0 33
Denmark 14 1 4 11 0 2 31
Germany 0  : 0 0 0 320 320
Estonia 1 1 4 0 3 0 8
Ireland 13 2 15 0 0 80 108
Greece 6 11 0 0 1 5 12
Spain 131 129 0 32 45 0 208
France 11 11 0 0 33 0 44
Croatia 30 : 0 0 0 0 30
Italy 708 798 0 0 0 0 708
Cyprus 1 1 0 0 2 0 3
Latvia 3 2 1 0 0 0 4
Lithuania 15 19 10 0 0 0 25
Luxembourg 2 1 0 0 0 0 2
Hungary 10 14 2 1 1 0 14
Malta 3 7 1 2 1 0 7
Netherlands 4 8 0 0 0 76 80
Austria 0 9 0 22 2 0 24
Poland 59 85 12 0 8 0 79
Portugal 68 57 0 0 0 0 68
Romania 5 3 2 0 5 0 12
Slovenia 7 4 0 0 0 0 7
Slovakia 13 19 0 0 0 20 33
Finland 0 4 0 0 0 75 75
Sweden 0 1 0 0 0 311 311
United Kingdom 18 10 40 27 0 53 138
Turkey 0  :  :  :  :  :  :
Norway 4 5 10 26 25 0 65
Total 1 160 1 223 104 163 131 942 2 500
Note: ‘:’ means ‘no data’.
(1)  Data on therapeutic community (TC) programmes reported in this publication are sourced from the Reitox national focal points (NFPs) network. In most countries, 
different numbers of TCs per country were identified in the context of a research study focused on TCs in Europe (EMCDDA Insights, 2014) because of the extended 
data sources used. The results from the two different data collections are presented in separate columns; the figures reported by the NFPs are used in the present 
analysis. 
(2) Czech Republic: reporting range, n = 15–20 TCs, of which the mean (n = 18) is taken for the calculation of the total number of residential facilities.
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I  Appendix 2
Sociodemographic characteristics and patterns of drug use among clients entering inpatient and outpatient treatment in 
selected countries in 2011
Number of clients 
Inpatient Outpatient
Gender
Females 7 625/30 340 (25 %) 57 779/248 597 (23 %)
Males 22 715/30 340 (75 %) 190 818/248 597 (77 %)
Age at first use
<20 15 345/23 949 (64 %) 127 683/202 682 (63 %)
20–30 6 631/23 949 (28 %) 56 13/202 682 (28 %)
30–40 1 475/23 949 (6 %) 14 415/202 682 (7 %)
40 498/23 949 (2 %) 4 454/202 682 (2 %)
Age at entering treatment
<20 1 936/31 602 (6 %) 35 530/263 535 (13 %)
20–30 13 224/31 602 (42 %) 93 172/263 535 (35 %)
30–40 10 416/31 602 (33 %) 83 267/263 535 (32 %)
40 6 026/31 602 (19 %) 51 566/263 535 (20 %)
Source of referral
Self-referred/family/friends 9 234/30 238 (31 %) 100 603/243 860 (41 %)
Other drug treatment centres 8 375/30 238 (28 %) 18 36/243 860 (8 %)
General practitioner/hospital/other medical source/social services 9 390/30 238 (31 %) 51 523/243 860 (21 %)
Court/probation/ police 1 768/30 238 (6 %) 58 701/243 860 (24 %)
Other 1 471/30 238 (5 %) 14 673/243 860 (6 %)
Educational level
Basic education (*) 7 005/22 420 (31 %) 26 759/243 860 (22 %)
Living status
Living alone 8 265/23 470 (35 %) 40 002/137 410 (29 %)
Living alone with child 1 297/23 470 (6 %) 8 455/137 410 (6 %)
Living in unstable accommodation 3 696/23 470 (16 %) 13 557/131 356 (10 %)
Labour status
Unemployed 15 365/25 374 (61 %) 102 658/214 520 (48 %)
Primary drug
Opioids 13 910/30 887 (45 %) 123 592/246 239 (50 %)
Cocaine 1 766/30 887 (6 %) 21 159/246 239 (9 %)
Amphetamines 5 015/30 887 (16 %) 15 635/246 239 (6 %)
Cannabis 4 745/30 887 (15 %) 74 286/246 239 (30 %)
Frequency of use (daily users)
Opioids 4 041/7 923 (51 %) 31 010/49 477 (63 %)
Cocaine 372/1 355 (27 %) 1 665/6 316 (26 %)
Amphetamines 1 415/4 597 (31 %) 1 859/9 973 (19 %)
Cannabis 1 590/4 337 (37 %) 20 923/46 045 (45 %)
All drugs 9 196/21 236 (43 %) 59 162/121 151 (49 %)
Route of administration (injecting)
Opioids 6 261/21 236 (29 %) 43 792/121 847 (36 %)
Cocaine 774/4 753 (16 %) 2 497/27 685 (9 %)
Amphetamines 2 226/9 172 (24 %) 2 127/23 886 (9 %)
All drugs 9 981/44 905 (22 %) 49 206/272 921 (18 %)
Notes: 
Only countries reporting clients for both inpatient and outpatient treatment centre types are included. 
Countries included in the analysis (n = 20): Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Ireland, Greece, France, Croatia, Cyprus, Luxembourg, Hungary, 
Austria, Poland, Romania, Slovakia, Finland, Sweden (2010 data), the UK and Norway. 
(*) Basic education corresponds to the following International Classification of Education: never went to school/never completed primary school/primary level of 
education.
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